Clinical Trial Update: Multidose Safety and Tolerability Study of Dose Escalation of Liposomal Amikacin for Inhalation (ARIKACE™) [Phase 1, Phase 2]

View source ↗

Summary

A completed Phase 1/2 trial evaluating multidose safety and tolerability of dose-escalated liposomal amikacin for inhalation (ARIKACE) in cystic fibrosis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cystic Fibrosis

Drugs mentioned

• Arikace

Snippet

Sponsor: Insmed Incorporated | Conditions: Cystic Fibrosis | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2019-07-16